^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    AmoyDx® Master Panel

    Company:
    Amoy Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    12ms
    Resistance mechanism and microenvironment changes after PARPi treatment: Paired analysis of ovarian cancer samples pre and post treatment. (ASCO 2023)
    Our small-scale study confirmed that BRCA reversion mutation is one of the important resistance mechanisms of PARPi, and the reversion mutation is located near the germline pathogenic mutation to counteract the reading frame change caused by the frameshift mutation. The up-regulation of B-cell receptor, NK cytotoxic cytokine receptor interaction and other related pathways suggested that PARPi may activate immune response, and the changes in the levels of memory B cells, C7 and neutrophils also confirmed the results above. Epithelial mesenchymal transition induced by CCL18 may also lead to PARPi resistance and activate the NF-κb pathway simultaneously, increasing the inflammatory characteristics of TME.
    Tumor mutational burden • PARP Biomarker • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BRCA (Breast cancer early onset) • NGFR (Nerve Growth Factor Receptor) • CCL18 (C-C Motif Chemokine Ligand 18) • ZFHX4 (Zinc Finger Homeobox 4)
    |
    MYC amplification • BRCA mutation • NGFR expression
    |
    AmoyDx® HRD Focus Panel • AmoyDx® Master Panel
    1year
    Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma (clinicaltrials.gov)
    P=N/A; N=60; Completed; Sponsor:Zhejiang University
    New trial
    |
    AmoyDx® Master Panel
    over1year
    AmoyDx® Master Panel--Study reveals clinically relevant intertumoral heterogeneity of NSCLCs driven by MET Exon 14 skipping mutation (AmoyDx Press Release)
    "A study presented at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinically relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping (METex14 skipping)...All the samples were subjected to targeted RNA sequencing using the AmoyDx® Master Panel consisting of 2660 onco-immunology genes."
    Clinical data
    |
    AmoyDx® Master Panel